BOSTON—Harvard Business School (HBS) has announced the 10 recipients of the 2023-2024 Robert S. Kaplan (MBA 1983) Life Sciences Fellowship. Established in 2008, now in its 15th yearth And in its final year, the fellowship was established by Robert S. Kaplan, president and chief executive officer of the Federal Reserve Bank of Dallas, vice chairman of the Goldman Sachs Group, and Martin Marshall Professor. H.B.S.
The fellowship encourages qualified life science students to join HBS by awarding up to $20,000 to incoming MBA students. Past recipients of this award have demonstrated academic achievement and professional leadership roles in industry. Many of this year's awardees are students in the MS/MBA Biotechnology: Life Sciences joint degree program, which builds on students' existing biotechnology and life sciences knowledge and equips them with the latest business and scientific insights. You can put it on. Kaplan Fellows continue their life science careers after graduation, including applying for and completing the Blavatnik Fellowship in Life Science Entrepreneurship, which provides HBS graduates the opportunity to build life science ventures while developing leadership talents. We have expressed a strong commitment to doing so.
“This final group of Kaplan Fellows begin their HBS journey with diverse scientific backgrounds and are well-versed in the Boston school as well as in business,” said Robert Hackman, the Albert J. Weatherhead III Professor of Business Administration. “It will also bring tremendous value to the biotechnology and biotechnology communities.” Howard Cox Healthcare Initiative Professor. “We are thrilled to welcome this new generation of leaders to Harvard's thriving life sciences ecosystem.”
The 2023-2024 Kaplan Fellows are:
Thomas Adeyemi (MBA 2025)
Tom joins HBS after spending the past two years in life sciences consulting at LEK Consulting, based in its London office. At LEK, we range from business development strategy for European neurology-focused biotech companies developing initial assets to commercial due diligence for biopharmaceutical and pharmaceutical services companies for private his equity clients. , worked on various projects. Tom was also selected for three externships during his time at LEK, working in the US precision medicine team of a global biopharmaceutical company and developing the business case for two newly acquired assets for a UK-based pharmaceutical company. Develops and works for a private company focused on Africa. Stock fund. Before working at LEK, Tom played professional football for over 10 years in his league in England and at the same time completed a degree in Biology at the Open University and won the Royal Society of Biology's Student of the Year award. was awarded. An MS/MBA: Biotechnology candidate, Tom is excited about exploring ways to solve important challenges in healthcare through collaborative efforts across multiple disciplines.
Ricky Cordova (MBA 2025)
Ricky is a bioengineer and product designer who has worked across the life sciences, medical device, and digital health industries to solve unmet clinical needs in obstetrics and gynecology. After graduating from Stanford University and the University of Arizona, he joined the BIO5 Institute, an NIH-funded company that led to the development of new diagnostics, endoscopic devices, and AI/ML tools for the early detection of ovarian cancer. He helped lead research projects at multiple institutions. Centering his research career on design and entrepreneurship, he completed a Harvard HealthTech fellowship at Harvard Medical School with the aim of providing a virtual pelvic floor therapy program to postpartum women. Co-founded a startup company. Before starting school at HBS, he spent time working with large companies at IDEO to design innovative healthcare and life science products, and worked with Meta and the World Health Organization on global public health projects. I continue to use these skills as an independent design consultant. .
Zaid Haq (MBA 2025)
Prior to joining HBS, Zaid worked in the life sciences field for eight years. Zaid began his professional career at Deloitte after completing his undergraduate studies in bioengineering, focusing on strategic challenges across the biopharmaceutical industry. Zaid then moved into industry and took on a business development role at Oncoceutics, helping develop new treatments for pediatric brain tumors. Most recently, Zaid played a key role in the business development of Nanobiotix, where he spearheaded the licensing of the company's cutting-edge oncology drug, NBTXR3, to Johnson & Johnson. He is very grateful for the support of the Kaplan Fellowship to further explore innovations in the biotechnology field. He wants to grow as a leader who can advance new drug candidates and change the lives of patients around the world.
Lucia Johnson joins the program from the biotechnology industry. In the biotechnology industry, he held corporate strategy, business development, and operations roles for early and growth stage biopharmaceutical and health technology companies. Lucia has been with Roivant Sciences for two years, working directly with management to develop a subsidiary focused on areas of unmet medical need, including new treatments during the COVID-19 pandemic. I launched it. Passionate about developing innovative treatments to address mental health crises, Lucia is the founder of Teran, an early stage biotechnology company focused on neuropsychiatric disorders. I joined the company as a time employee. During her time at Teran, she managed medicinal chemistry, preclinical and clinical programs, as well as Teran's patent portfolio where she was named inventor. Lucia studied human biology and administrative science and engineering at Stanford University, where she developed a combination of scientific, analytical, and business skills that accelerated the translation of scientific research into cost-effective solutions. . As her Kaplan Fellow, she appreciates the opportunity to build an integrated scientific and business skill set that will help bridge the gap between bench and bedside.
Megan Kotlappa (MS/MBA 2025)
After studying biotechnology, finance, and healthcare management and policy at the Jerome Fisher Program in Management and Technology at the University of Pennsylvania, Megan began her career in healthcare investment banking at Goldman Sachs. There, she worked on transactions totaling more than $18 billion, including M&A, IPOs, and private investments. Megan then joined B Capital and entered her first life in science investing with her $500 million fund. She helped define Life's science investment strategy, value more than 300 companies, and develop a global valuation methodology for biotechnology companies. Through the support of the MS/MBA Biotechnology program and the Kaplan Fellowship, Megan will further her knowledge, channel her inner scientist to impact patients, and do what she believes is most important: with the people she loves. We look forward to giving people more time to spend with us. .
Lena Licht (MBA 2025)
After studying biochemistry and entrepreneurship at UCLA, Lena, fascinated by the intersection of science and business, earned a master's degree in biotechnology from Northwestern University's McCormick School of Engineering, studying bioprocess engineering and engineering management. She completed her master's studies as a synthetic biologist at LanzaTech, an environmental biotechnology company, where she developed her own production to optimize and convert carbon in exhaust gases into usable substances. The strain was designed using metabolic engineering. Prior to joining HBS, she worked as a purification development scientist at Eli Lilly in Indianapolis, where she designed and developed efficient and scalable purification processes for biologics. Lena moved into the role of technical services representative for Eli Lilly's pilot plant, which manufactures biologics for clinical trials. Here, she oversaw the design, planning, and execution of her GMP campaigns to bring safe and effective medicines to patients. As an MS/MBA candidate, Lena is excited to strengthen her acumen on the intersection of science and business and bring new treatments to market.
Matt Sears (MBA 2025)
After five years as a research scientist, Matt took a step back from the lab and joined HBS. He had the opportunity to work at the University of Pennsylvania and the Massachusetts Institute of Technology, where he contributed research investigating the molecular regulation of normal mammalian development, non-invasive potential therapy for Alzheimer's disease, and techniques to map brain structure and connectomes. . Most recently, Beam worked at Therapeutics, where he led the lab's efforts to develop gene therapies for central nervous system diseases using Beam's base editing technology as part of a partnership with Pfizer. Matt is excited to use his accumulated scientific expertise and his time at HBS to bridge the scientific and business sides of the biotechnology industry. He recognizes that we now have both the ability and the opportunity to transform lives through the prevention and recovery of serious diseases. Matt hopes to leverage what he has learned through his MS/MBA biotechnology program and the support of his Kaplan fellowship to enable the creation and expansion of transformative cell and gene therapies for vulnerable patient populations. Masu.
Alana Smith (MBA 2025)
Alanna joins HBS after eight years in the life sciences industry. Her career includes academic research, medical device startups, Gilead, Global Blood Cell Therapeutics, and several commercial roles at Pfizer. She was recently acquired by Pfizer from Global Blood Therapeutics where she was a member of the Rare Disease Global Marketing team where she supported the pipeline development of two sickle cell therapeutics. Prior to the acquisition, Alanna also helped launch the first polymerization inhibitor (Oxbryta) for the treatment of sickle cell disease. As a Kaplan Fellow, Alana hopes to learn how to bring rare disease drugs to market more efficiently.
Cody Transberger (MBA 2025)
Prior to joining HBS, Cody spent six years in the life sciences industry, first at Goldman Sachs, then Kasdin Capital, and most recently at Prime Medicine. At Prime, Cody helped lead strategic efforts across business development and portfolio/adaptive strategies, including Prime's efforts in non-genotoxic conditioning and CAR-T therapies. In addition to HBS, Cody also consults for his Atlas Venture, and he also serves on the board of Cure Rare Disaster, a nonprofit focused on personalized treatments. As a Kaplan Fellow, Cody will leverage HBS resources, the expertise of his faculty and classmates, and the depth of Harvard's broader ecosystem to develop new treatments for underserved patients. I'm excited to do it.
Lindsay Wong (MBA 2025)
Prior to joining HBS, Lindsay spent six years working as a bench scientist in both academia and industry. She began her career at the Schepens Eye Institute, where she focused her research on elucidating the molecular mechanisms of numerous retinopathy and exploring pathway biology amenable to pharmacological intervention. Most recently, she transferred her skills to industry, where she worked on her early-stage drug discovery in Biogen's ophthalmology research division. During this time, Lindsay served as the scientific lead for a program aimed at developing a first-in-class gene therapy drug for patients with retinitis pigmentosa. She spearheaded the preclinical development strategy and led the program from lead identification through clinical development. MS/MBA As a biotech candidate, Lindsay will build on my technical expertise with skills and business acumen to achieve my goal of leading a biotech company at the forefront of impact-driven science. I am thinking of doing so.